Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreements

Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreements

Article content

VANCOUVER, British Columbia, Oct. 31, 2023 (GLOBE NEWSWIRE) — Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with: (i) its previously announced Common Share Subscription Agreement (the “Opensky
Subscription Agreement”) with OpenSky Opportunities Fund Ltd. (“Opensky”) dated 10 March 2023; and (ii) a Common Share Subscription Agreement dated 25 October 2023 (the “Standalone Subscription Agreement”, and collectively with the Opensky Subscription Agreement, the “Subscription Agreements”) between the Company and an arms-length investor (the “Standalone Investor” and collectively with Opensky, the “Investors”), the Company has filed a shelf prospectus supplement (the “Prospectus Supplement”) to the Company’s Final Short Form Base Shelf Prospectus for the province of Québec and Amended and Restated Final Short Form Base Shelf Prospectus for each of the provinces of Canada, dated 28 January 2022 (together, the “Shelf Prospectus”).

Advertisement 2

Story continues below

Article content

The Prospectus Supplement provides, among other things, that the Company is qualifying the distribution of up to 7,360,000 common shares (each a “Share”) in the capital of the Company to the Investors under the Subscription Agreements at a price of $0.15 per Share for aggregate gross proceeds of up to $1,104,000.

Article content

The Company also announces today the closing of Share issuances under the Subscription Agreements (the “Offerings”). The Offerings resulted in the issuance of 7,360,000 Shares at a price of $0.15 per Share for aggregate gross proceeds of $1,104,000. The distribution of such Shares is qualified by the Prospectus Supplement. The Company will use the proceeds of the Offering as described in the Prospectus Supplement.

An application will be made to the Aquis Stock Exchange (“Aquis”) for the 7,360,000 new Shares to be admitted to trading. Admission is expected to take place, and dealings on Aquis in the Shares are expected to commence, at 08:00 on or around 3 November 2023.

Following Admission, the Company will have 52,567,458 Ordinary Shares in issue. Since the Company currently holds no shares in treasury, the total number of voting rights in the Company will therefore be 52,567,458. These figures may therefore be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA’s Disclosure Guidance and Transparency Rules.

Article content

Advertisement 3

Story continues below

Article content

The Prospectus Supplement and Base Shelf Prospectus are available on the Company website and on the Company’s profile on the System for Electronic Document Analysis and Retrieval (SEDAR+) at www.sedarplus.ca.

About
Mydecine
Innovations
Group
Inc.

Mydecine Innovations Group is a publicly traded, pre-revenue biopharmaceutical company that began operations in North America and Europe in early 2020. Mydecine was founded to increase physicians’ access to serotonin-modulating medicine. Recent research has demonstrated the therapeutic potential of psychedelic substances such as psilocybin and MDMA for treating intractable conditions such as pain, anxiety, depression, addiction, and PTSD, along with neurodegenerative disorders. Mydecine believes these compounds can be safer, more effective, and more accessible for patients and medical professionals through modern drug chemistry paired with artificial intelligence (AI). Through its exclusive partnership with Applied Pharmaceutical Innovation based at the University of Alberta, Mydecine is developing innovative medications for target indications with high mortality rates that have lacked innovation for decades and are controlled by dominant corporations. Mydecine developed several prodrug families, beginning with a psilocybin-derived smoking cessation drug undergoing a NIDA-funded trial at Johns Hopkins University. Mydecine is also developing MYCO-006—short-acting chemical analogs derived from MDMA for treating various conditions, including anxiety and pain. Mydecine utilises cutting-edge artificial intelligence (AI) and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make them affordable and accessible to the general public upon Health Canada and FDA approval. The Mydecine team is enthusiastic about its mission and is dedicated to creating a positive difference in the lives of others.

See also  Ted Baker Announces Closure of 15 UK Stores, Resulting in Hundreds of Job Losses

Advertisement 4

Story continues below

Article content

The Directors of Mydecine take responsibility for this announcement.

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 (“MAR”), and is disclosed in accordance with the Company’s obligations under Article 17 of MAR.

Learn more at: https://www.mydecine.com/ and follow the company on Twitter, LinkedIn, YouTube, and Instagram.

For
more
information,
please
contact:

Media
Contact
pr@mydecineinc.com

Investor
Relations
investorrelations@mydecineinc.com

On
behalf
of
the
Board
of Directors

Joshua
Bartch,
Chief
Executive
Officer contact@mydecineinc.com

AQSE Corporate Advisor
Novum Securities Limited                Tel: +44 (0)207 399 9400
David Coffman/ George Duxberry

For further information about Mydecine, please visit the Company’s profile on SEDAR at https://sedar.com/ or visit the Company’s website at https://www.mydecine.com/.

Forward-Looking
Statements

Certain statements in this news release constitute “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking statements and information are provided for the purpose of providing information
about
management’s
expectations
and
plans
relating
to
the
future.
All
of
the
forward-looking
information
made in
this
news
release
is
qualified
by
the
cautionary
statements
below
and
those
made
in
our
other
filings
with
the
securities regulators in Canada. Forward-looking information contained in forward-looking statements can be identified by the use of words such as “are expected,” “is forecast,” “is targeted,” “approximately,” “plans,” “anticipates,” “projects,” “anticipates,”
“continue,”
“estimate,”
“believe”
or
variations
of
such
words
and
phrases
or
statements
that
certain
actions, events or results “may,” “could,” “would,” “might,” or “will” be taken, occur or be achieved. All statements, other than statements
of
historical
fact,
may
be
considered
to
be
or
include
forward-looking
information.
This
news
release
contains forward-looking
information
regarding, the
use
of
proceeds
and
the
closing
of
the
Offering.
Readers
are
cautioned
that these
forward-looking
statements
are neither promises nor guarantees, and are subject to risks and uncertainties that may
cause
future
results
to differ materially from those expected. Although the Company has attempted to identify important factors
that
could
cause
actual
results
to
differ
materially
from
those
contained
in
forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information.

Advertisement 5

Article content

The forward-looking information set forth herein reflects the Company’s reasonable expectations as at the date of this news release and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any
forward-looking information, whether
as a result of new information, future
events or
otherwise, other
than as required by law. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.

This
news
release
shall
not
constitute
an
offer
to
sell or
the
solicitation
of
an
offer
to
buy
nor
shall
there
be any sale
of
the
securities
in
any
State
in
which
such
offer,
solicitation
or
sale
would
be
unlawful.
The
securities
being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration
requirements
of
the
United
States
Securities
Act
of
1933,
as
amended,
and
applicable
state
securities laws.

MYDECINE INNOVATIONS GROUP INC.
Suite 810–789 West Pender Street, Vancouver, British Columbia, V6C 1H2 T: 604-687-2038

Article content

Comments

Postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. Comments may take up to an hour for moderation before appearing on the site. We ask you to keep your comments relevant and respectful. We have enabled email notifications—you will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. Visit our Community Guidelines for more information and details on how to adjust your email settings.

Join the Conversation

This Week in Flyers

Leave a Reply

Your email address will not be published. Required fields are marked *